Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Funding

Approval  ·  Weekly Digest 08 March to 14 March 2025
Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) approved for marketing in second indication by NMPA for EGFRm NSCLC

Weekly Digest – March 2025 Weekly Digest – March 2025 10 Mar 2025: Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) approved for marketing in second indication by NMPA for EGFRm NSCLC • Sichuan Kelun-Biotech’s TROP2-directed ADC, sac-TMT, is now approved in […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 08 March to 14 March 2025
Zai Lab announces acceptance of biologics license application for TIVDAK for the treatment of patients with recurrent or metastatic Cervical cancer

Weekly Digest – March 2025 Weekly Digest – March 2025 12 Mar 2025: Zai Lab announces acceptance of biologics license application for TIVDAK for the treatment of patients with recurrent or metastatic Cervical cancer Zai Lab announced that China’s NMPA […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest 08 March to 14 March 2025
ImmunoPrecise teases $10M ADC, bispecific collab with major biotech

Weekly Digest – March 2025 Weekly Digest – March 2025 13 Mar 2025: ImmunoPrecise teases $10M ADC, bispecific collab with major biotech ImmunoPrecise antibodies has partnered with a leading biotech company to develop antibody-drug conjugates and bispecific antibodies for cancer […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest 08 March to 14 March 2025
SOTIO Expands ADC Pipeline and Synaffix collaboration to develop two novel bispecific candidates, SOT112 and SOT113

Weekly Digest – March 2025 Weekly Digest – March 2025 13 Mar 2025: SOTIO Expands ADC Pipeline and Synaffix collaboration to develop two novel bispecific candidates, SOT112 and SOT113 SOTIO is exercising its option under the agreement with Synaffix to […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest 08 March to 14 March 2025
WuXi XDC and AbTis announce strategic partnership to advance next-generation ADCs

Weekly Digest – March 2025 Weekly Digest – March 2025 11 Mar 2025: WuXi XDC and AbTis announce strategic partnership to advance next-generation ADCs WuXi XDC, a leading CRDMO in ADCs, signed an MOU with AbTis, a south Korean ADC […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest 08 March to 14 March 2025
Immunome doses first patient in Phase 1 trial of IM-1021, a ROR1-targeted ADC

Weekly Digest – March 2025 Weekly Digest – March 2025 10 Mar 2025: Immunome doses first patient in Phase 1 trial of IM-1021, a ROR1-targeted ADC Immunome, Inc. has initiated the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC, […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 01 March to 07 March 2025
Celltrion receives FDA Phase 1 IND approval for next-generation ADC drug ‘CT-P70’

Weekly Digest – March 2025 Weekly Digest – March 2025 05 Mar 2025: Celltrion receives FDA Phase 1 IND approval for next-generation ADC Drug ‘CT-P70’ Celltrion received FDA approval for an Investigational New Drug (IND) application for its antibody-drug conjugate […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 01 March to 07 March 2025
Enhertu recommended for approval in the EU by CHMP for patients with HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy

Weekly Digest – March 2025 Weekly Digest – March 2025 28 Feb 2025: Enhertu recommended for approval in the EU by CHMP for patients with HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy Enhertu has been […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest 01 March to 07 March 2025
Callio Therapeutics launches with US$187 Million series A to advance multi-payload ADC platform through clinical proof-of-concept

Weekly Digest – March 2025 Weekly Digest – March 2025 03 March 2025: Callio Therapeutics launches with US$187 Million series A to advance multi-payload Antibody-Drug Conjugate platform through clinical proof-of-concept Callio Therapeutics launches with $187M Series A financing led by […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest 01 March to 07 March 2025
ENHERTU demonstrated statistically significant and clinically meaningful improvement in overall survival in patients with HER2 positive metastatic gastric cancer at interim analysis of DESTINY-Gastric04 Phase 3 trial

Weekly Digest – March 2025 Weekly Digest – March 2025 03 March 2025: ENHERTU demonstrated statistically significant and clinically meaningful improvement in overall survival in patients with HER2 positive metastatic gastric cancer at interim analysis of DESTINY-Gastric04 Phase 3 trial […]

by Sandhya Ramalingam

Continue Reading
« First‹ Previous505152535455565758Next ›Last »
Page 54 of 63


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id